GSDMD and Duchenne muscular dystrophy: This therapeutic benefit was mechanistically linked to the inhibition of the NLRP3-GSDMD axis, as evidenced by reduced levels of cleaved caspase-1 and N-terminal GSDMD, identifying pyroptosis as a previously unappreciated driver of pathology in DMD (Dubuisson et al., 2022).